Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Etoricoxib 120 mg vs Arcoxia in Healthy Volunteers
NCT03422575Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Dec 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etoricoxib in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 3 more (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Curve (0-t) at 72 hours and Maximum Plasma Concentration at 72 hours. Started Dec 2015; status: completed.
02
Drugs
etoricoxib
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)gouty arthritispain
Beyond the preview
Go deeper on NCT03422575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422575.